University of Massachusetts

Beth Israel Deaconess Medical Center, Inc.

Melissa Moore

Anastasia Khvorova

Anton A Turanov

Ananth Karumanchi

Phillip D Zamore

Erin E Heyer

Xin Li

Emiliano P Ricci

Christian Roy

Hakan Ozadam

Can Cenik

This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.

Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders

This disclosure provides methods and compositions for preparing and constructing cDNA libraries.

Compositions and methods for constructing cDNA libraries that allow for mapping the 5' and 3&#x2032; ends of RNAs

A technology is described that is capable of generating high-throughput sequencing (HTS) read length DNA products to accurately and reliably provide exon connectivity information for alternatively spliced isoforms. The method is not limited by the initial size of the isoform as the technology removes the template oligonucleotide sequence and a newly formed full length ligated product provides an HTS-compatible read length sequence that comprises information that corresponds to the consecutive order of the exons in the original template oligonucleotide.

Deducing exon connectivity by RNA-templated DNA ligation/sequencing

Growing community of inventors

Chestnut Hill, MA, United States of America

Melissa Moore